Interestingly, elderly patients with HER-2 + tumors did not significantly BCSS benefit from PMRT, with only a marginal survival advantage was shown for the HR+/ HER-2 + subtype in patients with T1-2N1 tumor. The gene discussed is ERBB2; the disease is neoplasm.